


# THE GLOBAL BURDEN OF CANCER

WITH **10** MILLION LIVES LOST EVERY YEAR, CANCER IS STILL A MAJOR CAUSE OF DEATHS WORLDWIDE<sup>1</sup>.

IN 2020, THE NUMBER OF NEW CASES WAS 19 MILLION AND IS ESTIMATED TO REACH 28 MILLION BY 2040<sup>1</sup>.



SUCH AN INCREASE WILL RESULT IN A TREMENDOUS LOSS OF LIFE AND COSTS TO SOCIETY.

INDEED, YEARLY COSTS OF ONCOLOGY PRESCRIPTION DRUGS PUT A HUGE PRESSURE ON HEALTHCARE SYSTEMS.

WITH A PRICE REDUCTION VARYING FROM

**9% TO 79%**

(COMPARED TO REFERENCE PRODUCTS), BIOSIMILARS COULD HELP REDUCE THESE SPENDINGS AND BENEFIT MORE PATIENTS<sup>2, 3</sup>.

FOR EXAMPLE, IN THE U.S., THE USE OF GENERIC DRUGS AND BIOSIMILARS SAVED \$18 BILLION ON ONCOLOGY MEDICINES IN 2020<sup>4</sup>.



#### References:

- (1) Sung H, Ferlay J, Siegal RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
- (2) Bangia I. Center for biosimilars. Biosimilar Discounts Vary by Category. 2020. Available at : <https://www.centerforbiosimilars.com/view/biosimilar-discounts-vary-by-category-> (accessed may 2023)
- (3) Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. BioDrugs. 2020;34(2):159-170.
- (4) Biosimilars Council. Biosimilar Medicines Produce Billions in Savings in U.S., Dramatically Reduce Oncology Spending Growth: Report. 2021. Available at: <https://biosimilarscouncil.org/news/biosimilar-medicines-produce-billions-in-savings-in-u-s-dramatically-reduce-oncology-spending-report/> (accessed may 2023)



**FRESENIUS  
KABI**  
BIOPHARMA